Geode Capital Management
MGX icon

Geode Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Geode Capital Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$480K Buy
358,200
+52,292
+17% +$81.2K ﹤0.01% 3594
2025
Q4 		$496K Buy
305,908
+14,018
+5% +$30.3K ﹤0.01% 3589
2025
Q3 		$692K Sell
291,890
-1,570
-0.5% -$3.19K ﹤0.01% 3506
2025
Q2 		$434K Sell
293,460
-326,114
-53% -$511K ﹤0.01% 3597
2025
Q1 		$843K Buy
619,574
+32,153
+5% +$76.6K ﹤0.01% 3362
2024
Q4 		$2.12M Buy
587,421
+249,390
+74% +$602K ﹤0.01% 3099
2024
Q3 		$734K Buy
338,031
+173,796
+106% +$603K ﹤0.01% 3464
2024
Q2 		$670K Buy
164,235
+77,472
+89% +$532K ﹤0.01% 3458
2024
Q1 		$915K Buy
+86,763
New +$997K ﹤0.01% 3398

Other funds holding MGX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management's MGX Position: Q1 2026 in Review

Geode Capital Management increased its Metagenomi Therapeutics (MGX) stake by 17% in Q1 2026, buying an estimated $81.2K and bringing the position to 358,200 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #3594.

Geode Capital Management first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.12M in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Geode Capital Management held 358,200 shares of Metagenomi Therapeutics worth $480K as of Q1 2026.
  • Geode Capital Management bought 52,292 Metagenomi Therapeutics shares in Q1 2026, an estimated $81.2K.
  • Metagenomi Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3594 holding.
  • Geode Capital Management first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Geode Capital Management's Metagenomi Therapeutics position peaked at $2.12M in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.